Efficacy and Safety of Mydriatic Regiments Used in Screening Retinopathy of Prematurity
Article Sidebar
Abstract
Background: ROP screening must be done under pupil dilation to examine the ocular fundus, in order to allow diagnosis and staging of ROP. The objectives of this literature review are to compare the efficacy and safety of topical cyclopentolate, phenylephrine, tropicamide and the combination of these regiments in infants for ROP screening.
Methods: The search was conducted through electronic databases providing journal articles with keywords: cyclopentolate, phenylephrine and tropicamide on pupil dilation and systemic side effects in infants on screening Retinopathy of prematurity.The baseline of pupil diameter, frequency of instillation, mean difference amount of dilated pupil size and diameter of the pupil in 30 or 45 minutes and 60 minutes are presented in outcome.
Results: The mydriatic agents used in this literature review were phenylephrine, tropicamide, cyclopentolate and the combination of those regiments. Doses of mydriatic agents used in this review are variables. The lowest dose for phenylephrine is 1%, cyclopentolate is 0.2% and tropicamide is 0.5%. The highest dose for phenylephrine is 2.5%, cyclopentolate is 1.0 % and tropicamide is 10 %. The use of mydriatic regiments during newborn ophthalmic examinations has been associated with systemic side effects. Most reports have implicated the sympathomimetic component of the mydriatic solutions as the hypertensive agents.
Conclusion: Using only cyclopegic regimens did not produce adequate mydriasis in infants. The combination of low concentration sympathomimetic (phenylephrine 1%) and parasympatholytic (Cyclopentolate 0.2 %) produces adequate pupillary dilation and does not cause an increase in blood pressure and heart rate.
Full text article
References
Novella CF, Viejo IG, Royo VP, Fernandes RM, Iztueta MG, Calvo JP et al. Screening program for retinopathy of prematurity in Spain. Arch soc esp oftalmol. 2013;88(5):184–8.
Quillen DA, Blodi BA. Clinical retina. United State of America: American Medical Association. 2002. p. 150-1.
An International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991-9.
Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Opth Soc. 2004;102:233-48.
Albert MD, Miller W, Cohan E, Perkins T. Principles and practice of ophthalmology. Wisconsin: WB Saunders Company. 2000. p. 4249-61.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol. 2001;119:1110–8.
Sitorus RS, Djatikusumo A, Andayani G, Barliana JD, Yulia DE. Pedoman nasional skrining dan terapi retinopathy of prematurity pada bayi premature di Indonesia. Jakarta. 2011. p. 12-4.
Staff American Academy of Ophthalmology. Basic and Clinical Science Course In Fundamental and Principles of Ophthalmology. San Francisco:American Academy of Opthalmology. 2011-2012. p. 334-46.
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford centre for evidence-based medicine; 2011. Available from http://www.cebm.net/ index.aspx?o=5653. Accessed November 4, 2013.
Creasy RK, Resnik R. Creasy and Resnik’s Maternal- Fetal Medicine: Principles and Practice, Seventh Edition. California: Saunders, an imprint of Elsevier. 2014. p. 624-53.
Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low weight infants. J Pediatr Ophthalmol Strabismus. 1981;18(6):42-4.
Isenberg S, Everett S, Parelhoff E. A Comparison of mydriatic eye drops in low weight infants. Ophthalmology. 1984;91:278-9.
Sindel BD, Baker MD, Maisels M, Weinstein J. A Comparison of the pupillary and cardiovascular effects of various mydriatic agents in preterm infants. J Pediatr Ophthalmol Strabismus. 1986;23(6):273-6.
Bolt B, Benz B, Koerner F, Bossi E. A mydriatic eye drop combination without systemic effects for premature infants: a prospective double blind study. J Pediatr Ophthalmol Strabismus. 1992;29(3):157-62.
Khoo B, Koh A, Cheong P, Ho N. Combination cyclopentolate and phenylephrine for mydriasis in premature infants with heavily pigmented irides. J Pediatr Ophthalmol Strabismus. 2000;37:15-20.
Chew C, Rahman RA, Shafie SM, Mohamad Z. Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides. J Pediatr Ophthalmol Strabismus. 2005;42:166-73.
Punyawattanaporn A, Tengtrisorn S, Sangsupawanich P. Pupil dilatation after single and triple doses of mydriatic agent in preterm infants. J Med Assoc Thai. 2009;92(11):1458-62.
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity, results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–96.
Ihekaire, DE. The comparative efficacy of cyclopegic drugs– tropicamide and cyclopentolate. International Journal of Scientific Research in Education. 2012;5(3):223-46.
Buyukcam A, Celik TH, Korkmaz A,Yurdakok M. Myoclonoc seizure due to cyclopentolate eye drop in preterm infant. The Turkish Journal of Pediatrics. 2012;54:419-20.
Carpel EF, Kalina RE. Pupillary responses to mydriatic agents in premature infants. Am J Ophthalmol. 1973;75:988-91.
Borromeo M, Bordiuk J, Keitel H. Systemic hypertension following ocular administration of 10% phenylephrine in neonates. Pediatrics. 1983;51:1032-36.
Fraunfelder F, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol. 1978;85:447-53.
Caputo AR, Schnitzer RE. Systemic response to mydriatic eye drops in neonates: mydriatics in neonates. J Pediatr Ophthalmol Strabismus. 1990;15:109-22.
Isenberg SJ, Abrams C, Hyman PE. Effects of cyclopentolate eyedrops on gastric secretory function in pre term infants. Ophthalmology. 1985;92:698-700.
Zimmerman T, Kooner KS, Kandarakis A, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551-3.
Alpay A, Ermis B, Ugurbas SC, Battal F, Sagdik HM. The local vasoconstriction of infant’s skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol. 2010;66:1161-4